Thomas John - Department of Medical Oncology, Austin Health/Olivia-Newton John Cancer Research Institute/School of Cancer Medicine, La Trobe University/Faculty of Medicine, University of Melbourne

基本信息

浏览量：193

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 221 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results

R.S. Herbst,Y.-L. Wu,C. Grohe,T. John, M. Majem, J. Wang, T. Kato,J.W. Goldman, S.-W. Kim,C.-J. Yu,H.V. Vu,G. Mukhametshina,

Journal of Thoracic Oncologyno. 3 (2023): e4-E4

引用0浏览0引用

Breathing in danger: how particulate matter pollution is putting the public at risk of lung cancer †

Adithya Balasubramanian,Thomas John,David J Adams

The Journal of pathology (2023)

引用0浏览0WOS引用

1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

M.L. Johnson, P.A. Jänne, Y. Goto, K. Yoh,S-H. Lee, L. Paz-Ares, B. Besse,S. Novello, H. Hayashi,D-W. Kim,T. John,S.C-H. Kao,

Annals of Oncology (2023): S760-S761

引用0浏览0引用

P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT

F. Hegi-Johnson,S. Rudd,P. Roselt,C. Wichmann,S. Sursock,T. Akhurst,P. Jackson,R. Hicks,A. Scott,P. Donnelly,T. John,M. MacManus

Journal of Thoracic Oncology（2023）

引用0浏览0引用

A tailored approach to horizon scanning for cancer medicines

Jennifer A Soon,Yat Hang To,Marliese Alexander,Karen Trapani,Paolo A Ascierto, Sophy Athan,Michael P Brown,Matthew Burge,Andrew Haydon,Brett Hughes,Malinda Itchins,Thomas John,

Journal of cancer policy (2023): 100441-100441

引用0浏览0WOS引用

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)

David P. Carbone,Tudor-Eliade Ciuleanu,Michael Schenker,Manuel Cobo-Dols, Stéphanie Bordenave-Juchereau,O. Juan-Vidal,J. Menezes,Niels Reinmuth,Eduardo Richardet, Ying Cheng,Hideaki Mizutani,Luis Paz‐Ares,

Journal of Clinical Oncologyno. 17_suppl (2023): LBA9023-LBA9023

引用1浏览0引用

Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations

J. C-H. Yang, M. Wang,C-H. Chiu, P-C. Hsu, P. Mitchell, C. L. Chang,T. M. Kim,T. John, L. Greillier,L. Bazhenova, E. Carcereny,A. I. Spira,

ANNALS OF ONCOLOGY (2023): S765-S765

引用0浏览0引用

Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC

M. P. MacManus,M. Alexander, J. Xie,D. Ball,B. Solomon,N. Plumridge,M. Shaw, S. Harden,F. Hegi-Johnson,S. Siva,T. John, A. Officer,

Journal of Thoracic Oncologyno. 11 (2023): S579-S579

引用0浏览0引用

Patterns of care for small cell lung cancer in Victoria, Australia: An observational cohort study

Joanna Huang,Wasek Faisal,Margaret Brand,Shantelle Smith,Marliese Alexander,Matthew Conron,Mary Duffy,Thomas John,David Langton, Jacqueline Lesage,Lisa Briggs,Michael MacManus,

RESPIROLOGY (2023): 42-43

引用0浏览0引用

Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians

H. L. Yeoh, P. L. Chia, B. Cowie,T. John

ANNALS OF ONCOLOGY (2023): S1712-S1712

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn